Background
==========

Noncommunicable diseases (NCDs) have become increasingly important in low- and middle-income countries (LMICs). Once considered a problem only in high-income countries (HICs), more and more patients who suffer from cancers and other NCDs are now observed in LMICs \[[@B1]\]. This is mainly due to the ageing populations and changing lifestyles in LMICs \[[@B2]\]. The global importance of NCDs has recently been acknowledged through the UN Summit on NCDs, held by the UN General Assembly in September 2011. As highlighted in the summit, the most prominent cause of cancer death among women in LMICs is breast cancer, accounting for 269,000 deaths (12.7% of all cancer deaths) in 2008 \[[@B3],[@B4]\].

In HICs, many efforts have been undertaken to control breast cancer, leading to various improvements in breast cancer outcomes \[[@B5],[@B6]\]. Strategies for breast cancer control are geared towards early detection and early treatment, and although its benefits are still open to discussion \[[@B7]-[@B9]\], mammography screening has been widely implemented \[[@B10]-[@B12]\]. In these countries, the selection of breast cancer control strategies has often been guided by economic analyses, demonstrating the value of alternative interventions \[[@B13]-[@B16]\].

In contrast to the established breast cancer control strategies in HICs, breast cancer is often neglected in LMICs and control strategies lack evidence-based information \[[@B17]-[@B20]\]. Policy-makers in LMICs cannot adopt similar breast cancer control strategies as implemented in HICs because most LMICs rely on much smaller budgets, and both the costs and effectiveness of control strategies are highly dependent on the population characteristics and the functioning of the health system \[[@B11],[@B20],[@B21]\].

Against this background, the present review provides an inventory of economic analyses of breast cancer control in LMICs. The paper's objectives are to present the available economic evidence from LMICs and to assess the methodological quality of the analyses. This research could improve the evidence base on cost-effective breast cancer interventions and could strengthen breast cancer control policy in LMICs.

Methods
=======

Search strategy and selection criteria
--------------------------------------

In this review, we analyzed publications from the MEDLINE index using PubMed, the Web of Science, Scopus, and Google Scholar. We searched the literature using the keyword 'breast cancer', combined with the keywords: 'developing countries', 'Asia', 'USSR', 'Middle-East', 'Eastern Europe', 'West-Indies', 'China', 'Russia', 'India', 'Africa', or 'limited resource', or combined with: 'cost-benefit', 'cost-effectiveness', 'costing', or 'cost analysis'. Additionally, we searched these indexes using 'breast neoplasms', 'developing countries,' and 'economics' in MeSH terms. Our search took place in January 2013, and was limited to publications in English. Studies were included only if they concerned breast cancer and originated from LMICs as listed by The World Bank \[[@B22]\].

The selection process is shown in Figure [1](#F1){ref-type="fig"}. In step 1, articles found by our search in the various indexes were merged in a database, which was then corrected for duplications (in Google Scholar, because of the large number of articles founds, we screened titles until the point that we did not find any further relevant title among the last 500 screened titles; in total, we screened 800 titles in this database). In step 2 we screened the titles of these articles, in step 3 the abstracts and in step 4 the remaining articles were read completely. We excluded publications for which no full-text article versions were available, or those not published in English. Furthermore, we excluded articles that only mentioned costs or cost-effectiveness without presenting original data.
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Study characteristics
---------------------

We documented the following characteristics from the reviewed articles: country or region, base year of cost data, study population, and breast cancer stage(s) considered. The stage was categorized as stage I to IV according to the American Joint Committee on Cancer \[[@B23]\].

We documented the following methodological characteristics: type of economic evaluation --cost analysis or cost of illness analysis, separately reported costs and effects, cost-effectiveness analysis, cost--benefit analysis, and cost--utility analysis; study design -- experimental, observational (cohort, case control, or cross-sectional), model based, and other designs; study perspective -- non-healthcare perspective (for example, productivity loss, travel costs, co-payments), healthcare perspective (for example, hospital administration costs, treatment costs), and societal perspective including non-healthcare and healthcare costs; time horizon; and outcome measure for effectiveness (disability-adjusted life years, quality-adjusted life years, life years saved, lives saved, and intermediate outcome measures).

The following qualitative characteristics were documented: sources for estimation of effectiveness, sources for estimation of resource utilization, discount rates used, sensitivity analysis for assumptions, and reported incremental analysis. We classified sources for estimation of effectiveness and resource utilization by primary data collection (for example, patients, questionnaires), secondary data collection (for example, records), literature based, expert opinion, and other. We also noted whether discount rates were used on costs, effects, both costs and effects, or not at all.

We also registered the study objective, the evaluated interventions, and the main study conclusions for each reviewed article.

Study evaluation
----------------

We used an established checklist by Drummond and Jefferson to judge the quality of the economic evaluations \[[@B24],[@B25]\]. A three-point response scale was added, similar to Gerard and colleagues \[[@B25]\], to more specifically grade the quality of each item on the checklist. Scores on this scale ranged from 0 (not considered), to 1 (partially considered) to 2 (fully considered). A few adjustments to the checklist by Drummond and Jefferson were necessary to create a more responsive scoring system for our particular set of economic studies. We removed those items that were not applicable to any of the reviewed studies (for example, on productivity changes), and combined some items that were otherwise putting too much emphasis to certain domains in the overall score (for example, on health state valuations and discount rates). The adapted checklist is provided in Table [1](#T1){ref-type="table"}. We summed up all scores, and compared this with the maximum attainable score to calculate the mean quality score of a study (as a percentage of the maximum attainable score). We accounted for items that were not relevant to the study under scrutiny (for example, studies that studied costs and effects in a single year were not criticized for not applying any discount rate in the analyses).

###### 

Checklist for quality of economic evaluations

  **Item**                                                                                                                        **Fully**   **Partial**   **Not at all**   **Not appropriate**
  ------------------------------------------------------------------------------------------------------------------------------- ----------- ------------- ---------------- ---------------------
  Original checklist                                                                                                              2 points    1 point       0 points         NA
  Study design                                                                                                                                                                
   1. The research question is stated                                                                                             □           □             □                □
   2. The economic importance of the research question is stated                                                                  □           □             □                □
   3. The viewpoint(s) of the analysis are clearly stated and justified (relating to a particular decision-making context)        □           □             □                □
   4. The rationale(s) for choosing the alternative programs or interventions which are compared is stated                        □           □             □                □
   5. The alternatives being compared are clearly described                                                                       □           □             □                □
   6. All relevant alternatives are included                                                                                      □           □             □                □
   7. The choice of economic evaluation is justified in relation to the questions addressed                                       □           □             □                □
  Effectiveness estimation                                                                                                                                                    
   8. The primary outcome measure for the economic evaluation is clearly stated                                                   □           □             □                □
   9. The source(s) of effectiveness estimates used is clearly stated                                                             □           □             □                □
   10. Details of the design and results of the effectiveness study are given (if based on a single study)                        □           □             □                □
   11. Details of the methods of synthesis or meta-analysis of estimates are given (if based on multiple studies)                 □           □             □                □
   12. Data and methods used to value health states and other benefits are stated and justified.                                  □           □             □                □
  Cost estimation                                                                                                                                                             
   14. Indirect non-healthcare costs are included or discussed                                                                    □           □             □                □
   15. Quantities of resources are reported separately from their unit costs                                                      □           □             □                □
   16. Methods for the estimation of quantities and unit costs are described and justified.                                       □           □             □                □
   17. Details of currency of price adjustments for inflation or currency conversion are given                                    □           □             □                □
  Analysis                                                                                                                                                                    
   18. Time horizon of costs and benefits are stated                                                                              □           □             □                □
   18. Details of any model used are given                                                                                        □           □             □                □
   19. The choice of model used and the key parameters on which it is based are justified                                         □           □             □                □
   20. The discount rate(s) is stated                                                                                             □           □             □                □
   21. The choice of rate(s) is justified                                                                                         □           □             □                □
   22. Details of statistical tests and confidence intervals are given for stochastic data                                        □           □             □                □
   23. Sensitivity analysis is performed:  2) Probabilistic (bootstrap/Monte Carlo)  1) Deterministic (one way /multiple way)     □           □             □                □
   24. The choice of variables in sensitivity analysis and the range over which these variables are varied is justified           □           □             □                □
   25. Incremental analysis is performed and reported                                                                             □           □             □                □
  Interpretation of results                                                                                                       □           □             □                □
   26. Major outcomes are presented in a disaggregated as well as aggregated form                                                 □           □             □                □
   27. The answer to the study question is given                                                                                  □           □             □                □
   28. Relevant alternatives are compared                                                                                         □           □             □                □
   29. Conclusions follow from the data reported                                                                                  □           □             □                □
   30. Conclusions are accompanied by the appropriate caveats such as generalizability, equity, feasibility, and implementation   □           □             □                □

This checklist was adapted from Drummond and Jefferson \[[@B24]\].

Two reviewers (SGZ and RMB) evaluated each publication for conformance with this checklist, and consensus was reached when scores differed. We followed PRISMA guidelines for reporting this systematic review.

Results
=======

Search results
--------------

The stepwise selection of articles by our selection criteria is presented in Figure [1](#F1){ref-type="fig"}. Our search strategy resulted in a total of 6,816 studies: 679 studies from PubMed, 328 studies from Web of Science, 5,009 studies from Scopus, and 800 from Google Scholar, respectively. In step 1, by merging the results of all individual search strategies and excluding duplication, the total number of hits was reduced to almost 4,400. Upon screening of titles (step 2), abstracts (step 3) and full texts (step 4), we eventually identified 24 articles that met our inclusion criteria.

Study characteristics
---------------------

Table [2](#T2){ref-type="table"} describes the baseline characteristics of the 24 included studies. We found eight studies from Asia, most concerning China, India and Iran. Five studies were on a global or sub-regional level, while there were five studies from Africa, three from Europe and three from Latin America. A total of 10 studies evaluated breast cancer screening in combination with treatment (*n* = 10), assessing mammography screening (*n* = 9), clinical breast examination (CBE) (*n* = 3), magnetic resonance imaging (*n* = 1), ultrasound (*n* = 1), biopsy (*n* = 1), elasticity imaging (*n* = 1), and tactile imaging (*n* = 1), respectively \[[@B26]-[@B36]\]. These studies evaluated a variety of age groups and screening frequencies (Table [3](#T3){ref-type="table"}). One study reported on a mass-media intervention to improve the early detection of breast cancer in Ghana \[[@B35]\]. Seven studies evaluated only treatment interventions including drug therapy (*n* = 4), oophorectomy (*n* = 1), radiotherapy (*n* = 1), and treatment in general (*n* = 1) \[[@B37]-[@B42]\]. Other studies examined the costs of diagnostic interventions (*n* = 3) or did not consider a specific intervention (*n* = 2) \[[@B43]-[@B48]\].

###### 

**Characteristics of reviewed studies**, **ordered by base year of cost data**

  **Authors**                                     **Region** / **country**                 **Base year of cost data**   **Study population**                                                                  **Breast cancer stage considered**   **Economic evaluation type**             **Study design**   **Perspective**   **Time horizon**   **Effectiveness outcome measure**   **Sources for estimation of effectiveness**   **Sources for estimation of resource utilization**   **Discount rates used**     **Sensitivity analysis for assumptions presented**   **Incremental analysis reported**
  ----------------------------------------------- ---------------------------------------- ---------------------------- ------------------------------------------------------------------------------------- ------------------------------------ ---------------------------------------- ------------------ ----------------- ------------------ ----------------------------------- --------------------------------------------- ---------------------------------------------------- --------------------------- ---------------------------------------------------- -----------------------------------
  Groot and colleagues, 2006 \[[@B28]\]           World sub-regions                        2000                         Female population at risk, in AfrE, AmroA, SearD                                      All                                  Cost-effectiveness analysis              Model based        Healthcare        100 years          DALYs                               Literature based                              Secondary data collection                            On both costs and effects   Yes                                                  Yes
  Okonkwo and colleagues, 2008 \[[@B30]\]         India                                    2001                         Female population at risk                                                             All                                  Cost-effectiveness analysis              Model based        Healthcare        25 years           Life years saved                    Secondary data collection                     Secondary data collection                            On both costs and effects   Yes                                                  Yes
  Munshi, 2009 \[[@B41]\]                         Worldwide                                Varying from 2002 to 2007    Breast cancer patients in general                                                     All                                  Report on costs and effects separately   Other              Healthcare        NA                 Intermediate outcome measures       Literature based                              Literature                                           NA                          NA                                                   NA
  Sarvazyan and colleagues, 2008 \[[@B32]\]       Worldwide                                Varying from 2003 to 2007    Female population at risk                                                             All                                  Cost-effectiveness analysis              Other              Not stated        1 year             Life years saved                    Literature based                              Literature                                           NA                          Yes                                                  No
  Fonseca and colleagues, 2009 \[[@B38]\]         Brazil                                   2005                         Hypothetical cohort of 64-year-old postmenopausal women                               All                                  Cost-effectiveness analysis              Model based        Healthcare        Lifetime           Life years saved                    Literature based                              Expert opinion                                       On both costs and effects   Yes                                                  Yes
  Ginsberg and colleagues, 2012 \[[@B27]\]        Sub-Saharan Africa and South East Asia   2005                         Female population at risk, in SearD and AfrE                                          All                                  Cost-effectiveness analysis              Model based        Healthcare        100 years          DALYs                               Literature based                              Secondary data collection                            On both costs and effects   Yes                                                  Yes
  Salomon and colleagues, 2012 \[[@B31]\]         Mexico                                   2005                         Female population at risk                                                             All                                  Cost-effectiveness analysis              Model based        Healthcare        100 years          DALYs                               Literature based                              Secondary data collection                            On both costs and effects   Yes                                                  Yes
  Pakseresht and colleagues, 2011 \[[@B48]\]      India                                    2006/2007                    103 women with primary breast cancer in a tertiary hospital                           All                                  Cost analysis/cost of illness            Observational      Non-healthcare    2 years            NA                                  NA                                            Primary data collection                              NA                          NA                                                   NA
  Yazihan and Yilmaz, 2006 \[[@B34]\]             Turkey                                   2007                         Female population at risk                                                             All                                  Cost-effectiveness analysis              Other              Healthcare        6 years            DALYs                               Secondary data collection                     Secondary data collection                            None                        No                                                   No
  Bastani and Kiadaliri, 2012 \[[@B49]\]          Iran                                     2008                         Patients younger than 75 with node-positive breast cancer                             All                                  Cost-utility analysis                    Experimental       Healthcare        8 months           QALYs                               Primary data collection                       Primary data collection                              NA                          No                                                   NA
  Liubao and colleagues, 2009 \[[@B39]\]          China                                    2008                         Model cohort of 1,000 51-year-old operable breast cancer patients                     All                                  Cost-effectiveness analysis              Model based        Healthcare        Lifetime           QALYs                               Secondary data collection                     Secondary data collection                            On both costs and effects   Yes                                                  Yes
  Astim, 2011 \[[@B36]\]                          Turkey                                   2010                         Female population at risk older than 30                                               All                                  Report on costs and effects separately   Model based        Healthcare        10 years           Intermediate outcome measures       Secondary data collection                     Literature                                           Yes                         No                                                   No
  Zelle and colleagues, 2012 \[[@B35]\]           Ghana                                    2010                         Female population at risk                                                             All                                  Cost-effectiveness analysis              Model based        Healthcare        100 years          DALYs                               Literature based                              Primary data collection                              On both costs and effects   Yes                                                  Yes
  Bai and colleagues, 2012 \[[@B42]\]             China                                    2012                         Model cohort of women aged 51.7, with early stage breast cancer after lumpectomy      1 and 2                              Cost-effectiveness analysis              Model based        Healthcare        Lifetime           QALYs                               Literature based                              Literature/expert opinion                            On both costs and effects   Yes                                                  Yes
  Arredondo and colleagues, 1995 \[[@B43]\]       Brazil                                   Not clear                    Hypothetical breast cancer case                                                       All                                  Cost analysis/cost of illness            Observational      Healthcare        NA                 NA                                  NA                                            Expert opinion                                       NA                          No                                                   No
  Boutayeb and colleagues, 2010 \[[@B37]\]        Morocco                                  Not clear                    Early-stage breast cancer patients in Morocco                                         Not clear                            Cost-effectiveness analysis              Observational      Healthcare        1 year             Life years saved                    Literature based                              Secondary data collection                            NA                          No                                                   No
  Denewer and colleagues, 2010 \[[@B26]\]         Egypt                                    Not clear                    Female population at risk between 25 and 65 years                                     All                                  Report on costs and effects separately   Experimental       Healthcare        2 years            Intermediate outcome measures       Primary data collection                       Not clear                                            None                        No                                                   No
  Guggisberg and colleagues, 2011 \[[@B46]\]      Cameroon                                 Not clear                    Women who underwent FNA in a rural hospital                                           All                                  Report on costs and effects separately   Observational      Healthcare        5 weeks            Intermediate outcome measures       Primary data collection                       Not clear                                            NA                          No                                                   No
  Kobayashi, 1988 \[[@B44]\]                      Worldwide                                Not clear                    NA                                                                                    NA                                   Cost analysis/cost of illness            Observational      Healthcare        NA                 Intermediate outcome measures       Primary data collection                       Primary data collection                              NA                          NA                                                   NA
  Love and colleagues, 2002 \[[@B40]\]            Vietnam and China                        Not clear                    Premenopausal Vietnamese and Chinese breast cancer patients, considered for surgery   2                                    Cost-effectiveness analysis              Experimental       Healthcare        15 years           Life years saved                    Primary data collection                       Not clear                                            On both costs and effects   No                                                   Yes
  Mousavi and colleagues, 2008 \[[@B29]\]         Iran                                     Not clear                    Female population at risk between 35 and 69                                           All                                  Report on costs and effects separately   Other              Healthcare        1 year             Life years saved                    Expert opinion                                Expert opinion                                       NA                          No                                                   No
  Nasrinossadat and colleagues, 2011 \[[@B47]\]   Iran                                     Not clear                    51 patients that underwent surgical excision of nonpalpable breast masses             All                                  Report on costs and effects separately   Observational      Healthcare        3 to 4 years       Intermediate outcome measures       Primary data collection                       Not clear                                            None                        No                                                   No
  Thomas and colleagues, 1999 \[[@B45]\]          Nigeria                                  Not clear                    Patients who received FNA between 1994 and 1997                                       All                                  Report on costs and effects separately   Observational      Patient           NA                 Intermediate outcome measures       Primary data collection                       Not clear                                            NA                          NA                                                   NA

DALYs, disability-adjusted life years; FNA, fine needle aspiration; NA, not applicable; QALYs, quality-adjusted life years.

###### 

**Interventions compared**, **study objectives**, **and main study conclusions of reviewed articles**

  **Authors**                                     **Interventions compared**                                                                                                                                                                **Study objective**                                                                                                                                                                                 **Conclusions by authors**
  ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Groot and colleagues, 2006 \[[@B28]\]           Combinations of individual stage I to IV treatment and an extensive mammography screening control program                                                                                 To assess the cost-effectiveness of breast cancer control that covers various interventions in different settings                                                                                   Stage I treatment and an extensive screening control program are the most cost-effective interventions
  Okonkwo and colleagues, 2008 \[[@B30]\]         Mammography screening, CBE screening among different age groups and in different frequencies                                                                                              To assess which screening program should be implemented in India                                                                                                                                    CBE screening in India compares favorably with mammography screening in developed countries
  Munshi, 2009 \[[@B41]\]                         Several treatment interventions                                                                                                                                                           To present pragmatic cost-saving breast cancer interventions                                                                                                                                        Intelligent use of knowledge about the disease can help us to exploit new techniques for maximum therapeutic gain with minimal investment
  Sarvazyan and colleagues, 2008 \[[@B32]\]       CBE, mammography, ultrasound, magnetic resonance imaging, biopsy, elasticity imaging, tactile imaging                                                                                     To review the diagnostic accuracy, procedure cost, and cost-effectiveness of currently available techniques for breast screening and diagnosis.                                                     Tactile imaging has the potential to provide cost-effective breast cancer screening and diagnosis
  Fonseca and colleagues, 2009 \[[@B38]\]         Anastrozole vs. tamoxifen in the adjuvant setting of early breast cancer                                                                                                                  To determine cost-effectiveness of anastrozole, compared with tamoxifen, in the adjuvant treatment of early stage breast cancer in Brazil                                                           Anastrozole is more cost-effective than tamoxifen in the adjuvant setting of early breast cancer
  Ginsberg and colleagues, 2012 \[[@B27]\]        Stage 1 to 4 treatment individual, treatment of all stages, biennial mammography screening 50 to 70 vs. null scenario                                                                     To determine the cost-effectiveness of 81 interventions to combat breast, cervical and colorectal cancer at different geographic coverage levels, to guide resource allocation decisions in LMICs   For breast cancer, although expensive, mammography screening in combination with treatment of all stages is cost-effective in both regions (I\$2,248 to 4,596/DALY). Treating early-stage breast cancer is more cost-effective than treating late-stage disease
  Salomon and colleagues, 2012 \[[@B31]\]         Stage 1 to 4 treatment individual, treatment of all stages, screening (annual CBE \>25 years + mammography annual \>50 years + mammography biennial \>40 to 49 years) vs. null scenario   Analyze the cost-effectiveness of 101 intervention strategies directed at nine major clusters of NCDs in Mexico (including breast cancer), to inform decision-makers                                Treatment of all stages is cost-effective and treatment of early stages is more cost-effective than late stage treatment. Nationwide screening has an incremental CEA of I\$22,000/DALY and is potentially cost-effective
  Pakseresht and colleagues, 2011 \[[@B48]\]      NA                                                                                                                                                                                        To estimate the expenditure audit of women with breast cancer in a tertiary hospital in Delhi                                                                                                       Expenditure on treatment for breast cancer depends on many factors, including the size and stage of the cancer, the woman\'s age, use of private hospitals and insurance
  Szynglarewicz and Matkowski, 2011 \[[@B33]\]    Polish screening program costs vs. other countries                                                                                                                                        To show preliminary results of the Polish screening program                                                                                                                                         Population-based mammographic screening conforming the European quality standards is cost-effective even for middle-income countries
  Yazihan and Yilmaz, 2006 \[[@B34]\]             Mammography screening in age group 50 to 69 vs. treatment only                                                                                                                            To determine the efficiency of resource usage in mammography screenings and the impact on breast cancer stages in Turkey                                                                            Mammography screening is economically attractive for Turkey
  Bastani and Kiadaliri, 2012 \[[@B49]\]          Docetaxel, doxorubicin and cyclophosphamide (TAC) vs. 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in node-positive breast cancer patients                                         To evaluate the cost-utility of TAC and FAC in node-positive breast cancer patients                                                                                                                 FAC was a dominant option versus TAC in the short term. In this study, TAC resulted in higher costs and lower QALYs over the study period
  Liubao and colleagues, 2009 \[[@B39]\]          AC (doxorubicin/cyclophosphamide) vs. TC (docetaxel/cyclophosphamide)                                                                                                                     To estimate the cost-effectiveness of AC (doxorubicin/cyclophosphamide) vs. TC (docetaxel/cyclophosphamide)                                                                                         TC appears to be more effective and more costly than AC. TC may be viewed as cost-effective using the general WHO threshold
  Astim, 2011 \[[@B36]\]                          Annual and biennial mammography screening in various age groups (40+, 45+, 50+, 55+, 60+ years) vs. no screening                                                                          To evaluate the cost-effectiveness, optimal minimum age and screening interval for a screening program in Turkey                                                                                    Results of the simulation suggests that women over 40 in Turkey should be screened by mammography biennially
  Zelle and colleagues, 2012 \[[@B35]\]           Treatment interventions, biennial mammography and CBE screening interventions, awareness raising interventions, palliative care interventions vs. null scenario                           To analyze the cost, effects and cost-effectiveness of breast cancer control interventions in Ghana, and identify the optimal mix of interventions to maximize population health                    Both screening by clinical breast examination and mass media awareness raising seem economically attractive interventions (\$1,299 and \$1,364/DALY). Mammography screening is not cost-effective
  Bai and colleagues, 2012 \[[@B42]\]             Radiotherapy vs. no radiotherapy after surgery                                                                                                                                            To assess the cost-effectiveness of additional radiotherapy for women with early breast cancer after breast-conserving surgery                                                                      In health resource-limited settings, the addition of radiotherapy is a very cost-effective strategy (−\$420/ QALY) in comparison with no-radio therapy in women with early breast cancer
  Arredondo and colleagues, 1995 \[[@B43]\]       Case management costs for infrastructure, human resources, laboratory, hospital stay, drugs, mastectomy, disposable material, curing material                                             To develop a system for monitoring costs of case management for each disease (breast cancer, cardiac calve disease and enteritis and bronchopneumonia)                                              Economic analyses hold important information for decision-making
  Boutayeb and colleagues, 2010 \[[@B37]\]        Three chemotherapy regimes, AC, AC + taxanes, AC + taxanes + trastuzumab                                                                                                                  To evaluate the total cost of chemotherapy in early stage breast cancer                                                                                                                             Moroccan health authorities need to devote between US\$13.3 to 28.6 million to treat women by chemotherapy every year
  Denewer and colleagues, 2010 \[[@B26]\]         CBE-based screening with selective mammography vs. no screening                                                                                                                           To evaluate the disease pattern of screen-detected cancers and determine the effectiveness of CBE-based screening                                                                                   CBE-based screening with selective mammography is feasible, effective and improves the results of breast cancer management in Egypt
  Guggisberg and colleagues, 2011 \[[@B46]\]      On-site FNA clinic vs. shipping of specimens                                                                                                                                              To assess the feasibility of an on-site cytopathology clinic in a rural hospital in Cameroon                                                                                                        Cytopathology (FNA) is a reliable alternative for tissue diagnosis in low-resource settings
  Kobayashi, 1988 \[[@B44]\]                      Costs and performance of breast echography in different institutions                                                                                                                      To analyze the economics and cost performance of breast echography in various institutions                                                                                                          The best cost performance, internationally, can be achieved by mechanical and real-time electronic linear scanners
  Love and colleagues, 2002 \[[@B40]\]            Adjuvant oophorectomy and tamoxifen vs. oophorectomy and tamoxifen for recurrence after observation.                                                                                      To evaluate costs, disease-free and overall survival after surgical oophorectomy and tamoxifen in premenopausal Vietnamese women with operable breast cancer                                        Vietnamese and Chinese women with hormone receptor-positive operable breast cancer benefit from adjuvant treatment with surgical oophorectomy and tamoxifen
  Mousavi and colleagues, 2008 \[[@B29]\]         Mammography screening in age groups 35 to 69 and 50 to 69 and no screening                                                                                                                To decide whether mammography screening should be established in Iran or whether other options are needed                                                                                           Benefits of other policies than mammography screening need to be explored
  Nasrinossadat and colleagues, 2011 \[[@B47]\]   Methylene blue dye injections vs. wire localization                                                                                                                                       To report experience in marking nonpalpable breast masses by injection of methylene dye                                                                                                             Marking with methylene blue dye is a simple, effective and low-cost method for localization of nonpalpable breast masses
  Thomas and colleagues, 1999 \[[@B45]\]          FNA cytology vs. surgical tissue biopsy                                                                                                                                                   To assess the results and limitations of a Nigerian FNA clinic                                                                                                                                      FNA cytology can help improve the management and cost of care of patients with palpable masses

CEA, cost-effectiveness analysis; CBE, clinical breast examination; DALY**,** disability-adjusted life year; FNA, fine needle aspiration; LMIC, low- and middle-income country; NCD, noncommunicable disease; QALY, quality-adjusted life year; WHO, World Health Organization.

The methodological study characteristics of the reviewed studies are presented in Table [2](#T2){ref-type="table"}. The base year of cost data in the included studies was generally not from before year 2000, and could not be identified in eight studies. The majority of studies combined both costs and effects in a single cost-effectiveness estimate (*n* = 13), and the majority of these were based on mathematical models (*n* = 9). Most studies used a healthcare perspective (*n* = 19), and only one study included non-healthcare costs \[[@B48]\]. Studies used a time horizon varying between 5 weeks and the lifetime of the study population. Most reviewed studies used intermediate outcome measures (that is, clinical effects *n* = 8), life years saved (*n* = 6), or disability-adjusted life years (*n* = 5) as their main effectiveness outcome, while quality-adjusted life years were less frequently used (*n* = 3).

Study quality
-------------

Table [4](#T4){ref-type="table"} summarizes the quality of the included studies, as indicated by the percentage score. The quality of all studies ranges from 23 to 86%. Studies by Ginsberg and colleagues, Zelle and colleagues, and Bai and colleagues had the highest total average scores, and these were all modeling studies \[[@B27],[@B35],[@B42]\]. If items were not applicable (NA) for a reviewed paper, the maximum obtainable (domain) score was reduced with 2 points per item.

Studies generally scored poorly on the domain 'estimation of costs', at an average 34% of the maximum obtainable score across all studies. The average score for 'study design' was 73%, while the quality of the domains 'estimation of effectiveness', 'analysis', and 'interpretation of results' was scores as 70%, 51%, and 68%, respectively.

Study findings
--------------

As described earlier, most studies evaluated breast cancer screening in combination with treatment. Studies in Mexico, Poland, Turkey identified mammography screening as a cost-effective intervention \[[@B31],[@B33],[@B34],[@B36]\], whereas studies in India, Ghana and Egypt found other strategies (such as CBE screening or mass-media awareness raising) to be economically more attractive (Table [3](#T3){ref-type="table"}) \[[@B26],[@B30],[@B35]\]. Sarvazyan and colleagues proposed another breast cancer screening option: tactile imaging as an alternative to several other interventions \[[@B32]\].

###### 

Summary of quality assessment and domain scores of reviewed studies

  **Authors**                                     **Scored domains**   **Summary scores**                                                                                                                                                        
  ----------------------------------------------- -------------------- -------------------- ------------------------------ --------------------- -------------- ------------------------------- ---------------------------- ------------------- -------------------------
                                                                       **Study design**      **Effectiveness estimation**  **Cost estimation**   **Analysis**   **Interpretation of results**    **Number of items scored**  **Sum of scores**   **Total average score**
  Groot and colleagues, 2006 \[[@B28]\]           Score granted        12                                 7                6                     16             9                                            29              50                  1.72
  \% of maximum (domain) score                    86%                  88%                               75%               89%                   90%                                                                         86%                 
  Okonkwo and colleagues, 2008 \[[@B30]\]         Score granted        12                                 6                3                     16             10                                           28              47                  1.68
  \% of maximum (domain) score                    86%                  100%                              38%               100%                  100%                                                                        84%                 
  Munshi, 2009 \[[@B41]\]                         Score granted        7                                  7                0                     1              4                                            21              19                  0.90
  \% of maximum (domain) score                    50%                  70%                                0%               50%                   40%                                                                         45%                 
  Sarvazyan and colleagues, 2008 \[[@B32]\]       Score granted        7                                  7                0                     1              4                                            21              19                  0.90
  \% of maximum (domain) score                    50%                  70%                                0%               50%                   40%                                                                         45%                 
  Fonseca and colleagues, 2009 \[[@B38]\]         Score granted        14                                 6                1                     13             10                                           28              44                  1.57
  \% of maximum (domain) score                    100%                 100%                              13%               72%                   100%                                                                        79%                 
  Ginsberg and colleagues, 2012 \[[@B27]\]        Score granted        12                                 8                8                     18             10                                           29              52                  1.79
  \% of maximum (domain) score                    86%                  100%                              75%               89%                   100%                                                                        90%                 
  Salomon and colleagues, 2012 \[[@B31]\]         Score granted        12                                 6                5                     14             8                                            29              45                  1.55
  \% of maximum (domain) score                    86%                  75%                               63%               78%                   80%                                                                         78%                 
  Pakseresht and colleagues, 2011 \[[@B48]\]      Score granted        7                                  1                4                     3              5                                            15              20                  1.33
  \% of maximum (domain) score                    88%                  50%                               50%               75%                   63%                                                                         67%                 
  Szynglarewicz and Matkowski, 2011 \[[@B33]\]    Score granted        5                                  3                2                     1              5                                            24              15                  0.625
  \% of maximum (domain) score                    88%                  50%                               50%               75%                   63%                                                                         33%                 
  Yazihan and Yilmaz, 2006 \[[@B34]\]             Score granted        12                                 0                3                     2              5                                            28              22                  0.79
  \% of maximum (domain) score                    86%                  0%                                38%               13%                   50%                                                                         40%                 
  Bastani and Kiadaliri, 2012 \[[@B49]\]          Score granted        13                                 8                4                     7              8                                            25              40                  1.6
  \% of maximum (domain) score                    93%                  100%                              50%               70%                   80%                                                                         80%                 
  Liubao and colleagues, 2009 \[[@B39]\]          Score granted        13                                 7                4                     16             10                                           29              50                  1.72
  \% of maximum (domain) score                    93%                  88%                               50%               89%                   100%                                                                        86%                 
  Astim, 2011 \[[@B36]\]                          Score granted        9                                  5                3                     8              7                                            28              32                  1.14
  \% of maximum (domain) score                    64%                  63%                               38%               50%                   70%                                                                         57%                 
  Zelle and colleagues, 2012 \[[@B35]\]           Score granted        14                                 7                7                     14             10                                           29              52                  1.79
  \% of maximum (domain) score                    100%                 88%                               88%               78%                   100%                                                                        90%                 
  Bai and colleagues, 2012 \[[@B42]\]             Score granted        13                                 8                5                     18             8                                            29              52                  1.79
  \% of maximum (domain) score                    93%                  100%                              63%               100%                  80%                                                                         90%                 
  Arredondo and colleagues, 1995 \[[@B43]\]       Score granted        10                                 NA               1                     0              7                                            18              18                  1.00
  \% of maximum (domain) score                    71%                  NA                                13%               0%                    70%                                                                         50%                 
  Boutayeb and colleagues, 2010 \[[@B37]\]        Score granted        12                                 4                4                     1              6                                            25              27                  1.08
  \% of maximum (domain) score                    86%                  50%                               50%               13%                   60%                                                                         54%                 
  Denewer and colleagues, 2010 \[[@B26]\]         Score granted        10                                 4                0                     2              5                                            25              21                  0.84
  \% of maximum (domain) score                    71%                  50%                                0%               20%                   50%                                                                         42%                 
  Guggisberg and colleagues, 2011 \[[@B46]\]      Score granted        3                                  6                2                     1              5                                            25              24                  0.96
  \% of maximum (domain) score                    21%                  75%                               25%               13%                   50%                                                                         35%                 
  Kobayashi, 1988 \[[@B44]\]                      Score granted        4                                  4                1                     NA             3                                            19              12                  0.63
  \% of maximum (domain) score                    29%                  67%                               13%               NA                    30%                                                                         32%                 
  Love and colleagues, 2002 \[[@B40]\]            Score granted        9                                  6                1                     10             8                                            27              34                  1.26
  \% of maximum (domain) score                    64%                  100%                              13%               63%                   80%                                                                         63%                 
  Mousavi and colleagues, 2008 \[[@B29]\]         Score granted        5                                  1                0                     1              3                                            22              10                  0.45
  \% of maximum (domain) score                    36%                  25%                                0%               13%                   30%                                                                         23%                 
  Nasrinossadat and colleagues, 2011 \[[@B47]\]   Score granted        75                                 5                0                     0              5                                            25              17                  0.68
  \% of maximum (domain) score                    50%                  63%                                0%               0%                    50%                                                                         34%                 
  Thomas and colleagues, 1999 \[[@B45]\]          Score granted        7                                  4                0                     0              6                                            21              17                  0.81
  \% of maximum (domain) score                    50%                  67%                                0%               0%                    60%                                                                         41%                 
  Total average domain score (%)                  73%                  70%                               34%               51%                   68%                                                                                             

Studies evaluating treatment interventions typically favored the novel interventions. Anastrozole was more cost-effective than tamoxifen in a Brazilian study \[[@B38]\], oophorectomy and tamoxifen after recurrence was shown to be favorable in Vietnamese and Chinese patients \[[@B40]\], additional radiotherapy after breast-conserving surgery was very cost-effective in China \[[@B42]\], and chemotherapy consisting of a docetaxel and cyclophosphamide regimen was more attractive compared with an doxorubicin and cyclophosphamide regimen also in Chinese patients \[[@B39]\]. There was only one study with a negative suggestion for the novel and more costly intervention docetaxel, doxorubicin, cyclophosphamide, as compared with the more conventional 5-fluorouracil, doxorubicin, dyclophosphamide regime \[[@B49]\].

Studies that only assessed costs and did not include effectiveness estimates, reported on costs of breast cancer for patient management in Brazil (US\$1,646 per patient) \[[@B43]\], and the costs of patient expenditure (US\$242 per patient) in India \[[@B48]\].

The three studies evaluating diagnostic interventions demonstrated the economic attractiveness of inexpensive interventions; that is, fine-needle aspiration cytology and methylene blue dye injections \[[@B45]-[@B47]\]. These interventions could be especially relevant for diagnosing breast cancer in rural settings and settings with low resources.

Discussion
==========

This study shows that there is limited economic evidence on breast cancer control in LMICs. Only 24 economic evaluation studies were found in this review, and their quality was generally poor. Furthermore, the study populations were very diverse, as most studies examined different kinds of screening and therapeutic interventions in various age and risk groups. Owing to this poor availability, quality, and comparability, we conclude that the economic evidence base to guide strategies for breast cancer in LMICs is currently insufficient.

Our review raises a few discussion points. First, there is mixed evidence on the economic attractiveness of mammography screening. Studies in Mexico, Poland and Turkey demonstrate the intervention to be cost-effective, whereas studies in India, Ghana, and Egypt suggests that other forms of screening -- for example, by CBE -- provide more value for money. The evidence base is too small to generalize these findings to other LMICs, and to draw general conclusions. Also, most of the studies evaluating therapeutic interventions seem to favor the more novel -- and often more expensive -- therapy. These findings may be explained by many reasons, including the higher effectiveness of the novel interventions but possibly also the association between funding sources and pro-industry conclusions \[[@B50]\].

Second, in general, we found that the quality of the reviewed articles was poor. The majority of studies failed to score at least 50% on every domain ('study design', 'estimation of effectiveness', 'estimation of costs', 'analysis', and 'interpretation of results'). These domain scores further show that most emphasis was given to the design of the studies and the interpretation of results, whereas costs, in particular, were poorly evaluated. This calls for better adherence of studies to methodological standards for economic analyses, or the development of such standards specifically for breast cancer research. Future studies could be improved by using a checklist, and through transparent reporting of the items in checklists \[[@B25],[@B51]\].

Third, the current evidence base leaves many LMICs with the difficult task of extrapolating results from other countries. The transferability of economic evaluations across countries is complicated, as clinical practice patterns, healthcare systems, and cultural and ethical practices differ across countries \[[@B52],[@B53]\]. Standardized ways of adopting economic evaluations, with the help of available checklists and guidelines \[[@B24],[@B25],[@B51],[@B54]-[@B58]\], may improve this lack of transferability. Alternatively, modeling studies could play an important role in extrapolating results from one context to another. Modeling studies, however, rely on the availability of costing and effectiveness data, and this emphasizes the need for more primary data collection on these aspects in LMICs. With data from such studies, researchers would not have to continue to rely on sensitivity analyses or extrapolating cost estimates from data in HICs. National cancer registries, mortality databases, hospital registries, and accessible publications would be essential for providing such information \[[@B59]\].

Fourth, and closely related, we generally advocate the use of modeling studies in the economic analysis of breast cancer control in LMICs. In addition to their use in the extrapolation of study findings, they generally appeared to be of high quality, are sufficiently flexible to include important methodological characteristics such as adequate time horizon, and seem also appropriate to evaluate a broad array of interventions across different groups.

Fifth, the most adopted type of economic evaluation was cost-effectiveness analysis, using a healthcare perspective and life years saved as the primary outcome. Although cost-effectiveness analyses using a healthcare perspective contribute very important information, productivity losses for patients suffering from breast cancer -- and most probably other NCDs -- can be substantial \[[@B60],[@B61]\]. So far, there is no methodological consensus on estimating productivity loss and the cost of illness can vary greatly between different costing approaches (for example, human capital approach vs. friction cost approach) and also between gender, age and the type of job of patients \[[@B62]\]. Further research should account for economic and social characteristics of the population under study, and should try to investigate productivity losses. Additionally, life years saved may be a less appropriate outcome when palliative or preventive interventions are investigated, and the use of disability-adjusted or quality-adjusted life years may be more appropriate.

Sixth, there is currently very little economic evidence on less established interventions such as tactile imaging, awareness raising, CBE screening, or preventive and palliative interventions. Economic studies, especially in LMICs, should aim to evaluate these interventions more often (and thereby including broad target populations) as they have the potential to be economically attractive \[[@B26],[@B30],[@B32],[@B35]\].

Finally, guidance in decision-making and recommendations for implementation are generally underemphasized in economic evaluations. By reflecting on the health system characteristics of the particular country and considering them in implementation recommendations, economic evaluations could improve their use in breast cancer policy development.

Our study has a number of limitations. Primarily, the number of articles reviewed is very limited, possibly the result of our search strategy. Besides a possible publication bias -- studies with negative outcomes are less likely to be published -- we searched only for articles published in English. This may explain the relatively small number of articles found, for instance, from Spanish-speaking regions or from countries where there is less emphasis on publishing research (for example, in Africa). Also, the studies included in our review vastly differed with regard to their methodology, objectives, characteristics, and study populations and hence are difficult to compare. In addition, our quality assessment of the reviewed articles was based on a checklist that gives highest scores to a full reporting of all domains. However, short reports in the form of, for example, editorials may not include all these details but may nevertheless be valid for the goals they serve. Hence, the scores for these studies should be interpreted with caution.

Conclusions
===========

To conclude, our findings indicate that research on the costs and cost-effectiveness of breast cancer control in LMICs is still in its infancy. The limited evidence base suggests that screening strategies may be economically attractive in LMICs -- yet there is very little evidence to provide specific recommendations (on screening by mammography vs. CBE, the frequency of screening, or the target population). These results demonstrate the need for more economic analysis that are uniform, of better quality, cover a comprehensive set of interventions and result in clear policy recommendations.
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